FIB-4 is a validated non-invasive screening tool for liver fibrosis that combines age, AST, ALT, and platelets.
FIB-4 is a validated non-invasive screening tool for liver fibrosis that combines age, AST, ALT, and platelets. It has an extremely high negative predictive value — a low FIB-4 reliably rules out advanced fibrosis without invasive testing, making it one of the most useful metabolic-liver screens in primary care.
Elevated values point to non-alcoholic fatty liver disease (NAFLD / MASH), alcoholic liver disease, chronic viral hepatitis, autoimmune hepatitis, drug-induced injury, or haemochromatosis. Metabolic syndrome and obesity are the dominant modern drivers.
Early-stage fibrosis is typically silent. Fatigue, right-upper-quadrant discomfort, or unexpected weight loss warrant hepatology review independent of FIB-4 values.
Mediterranean-pattern eating, 2–3 cups of coffee daily (robust liver-protective evidence), cruciferous vegetables, fatty fish, and olive oil. Weight loss of 7–10% reverses early fibrosis in NAFLD.
Alcohol is the single most modifiable driver — even moderate intake compounds metabolic fibrosis risk. High-fructose beverages, ultra-processed foods, and unnecessary paracetamol use.
Educational information only — not a diagnosis. Every Pheno result is interpreted in context and reviewed by a physician.
See all 119 markers we test →